Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359159 | 0.80 | IDO1 (0.53) | KDM4EGRM2TSHRSLC9A1NPSR1 | |
| SCHEMBL28331497 | 0.80 | CYP19A1 (0.58) | KDM4EGRM2TSHRSLC9A1POLB | |
| SCHEMBL13844987 | 0.78 | SMN1; SMN2 (0.42) | TSHRNPSR1POLBLMNAKMT2A | |
| SCHEMBL15937046 | 0.78 | POLB (0.55) | GRM2TSHRSLC9A1POLBIDO1 | |
| SCHEMBL795210 | 0.78 | HPGD (0.68) | TSHRPOLBKMT2AGAAHPGD | |
| SCHEMBL11948732 | 0.78 | ALDH1A1 (0.58) | KDM4EGRM2TSHRSLC9A1NPSR1 | |
| SCHEMBL17283083 | 0.76 | PFKFB3 (0.58) | TSHRPOLBLMNAKMT2AGAA | |
| SCHEMBL17359178 | 0.76 | HPGD (0.50) | GRM2TSHRSLC9A1POLBIDO1 | |
| SCHEMBL28713137 | 0.76 | CYP2C19 (0.46) | KDM4EGRM2TSHRSLC9A1NPSR1 | |
| SCHEMBL15924211 | 0.75 | HPGD (0.60) | TSHRPOLBKMT2AGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119968373-A | Aromatic heterocyclic compound and preparation method thereof | 上海翊石医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025051214-A1 | AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR | 上海翊石医药科技有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885GRM2 17/4885TSHR 1558/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | KDM4E 3857/4885GRM2 301/4885TSHR 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.